+34 679 490 537info@nanbiosis.com

JUMISC

JUMISC

III Course on Introduction to research and laboratory techniques in Biosciences

CCMIJU has organised the III Course on Introduction to research and laboratory techniques in Biosciences, which wil take place at JUMISC on December, 18th, 2020 under the Direction of Esther López Nieto and Javier García Casado, Scientific Director of NANBIOSIS U14 Cell Therapy. Other researchers of NANBIOSIS Units offer their expertise as Beatriz Moreno Lobato, Scientific Diector NANBIOSIS U19 and Luis Dávila Gómez, Scientific Director of NANBIOSIS U22

The course contents are distributed in the following blocks:

Block I. Knowledge pills for research – Theory
Research career and aid for hiring (Dr JG Casado). 30 min
Communication of research results (Dra. E López). 30 min
Introduction to bibliographic resources. (Dra. R Blázquez). 30 min
Research Projects: preparation and evaluation (Dr JG Casado). 30 min
Protection of research results. Intellectual and industrial property. (JL Añover). 30 min

Block II. Knowledge pills for research – exercises / case studies
Practical case 1: Bibliographic search and Commentary and assessment of different scientific communications: 1.5h
Block III. RNA and DNA: gene expression and genetic studies in reproduction
Introduction to the analysis of gene expression using qPCR (F Marinaro and E López). 1h 30min
Pre-implantation genetic diagnosis in assisted reproduction clinics (E Delgado). 1 hour

Block IV. Proteins and proteome: protein expression studies and massive proteomics analysis / identification
Protein expression study I: Introduction to immunoprecipitation and western blotting techniques (E López). 1 hour
Introduction to the study of proteins II: Generalities and principles of proteomics in cardiovascular research (I Jorge). 1h 30min

Block V. Cell cultures: stem cell cultures and production for clinical uses
Cell cultures I: Isolation of adult stem cells and characterization (R Blázquez). 1 hour
Cell cultures II: Production, commercialization and clinical uses of cell therapy (O delaRosa). 1h 30min

Block VI. Miscelanea: Histology, clinical analysis, 3D bioprinting and animal experimentation
Basic fixation, inclusion and staining techniques for histology (A Usón). 1 hour
Basic techniques for determining blood parameters: Biochemistry and hematology (B Moreno). 1 hour
Technology and materials in the 3D bioprinting laboratory (JC Gómez). 1 hour
Minimally invasive experimental procedures in laboratory animals (L Dávila). 1 hour

Block VII: Laboratory techniques in biosciences – exercises / practical cases
Practical case-example 2: Analysis of qPCR results. 1,5h

Further information: Programm and inscriptions

Read More

XIV COURSE OF LAPAROSCOPIC SURGERY OF COLON

CCMIJU has organised the XIV Course of Laparoscopic Surgery of Colon, which wil take place at JUMISC from 14 December to 16 December 2020 under the Direction Francisco Miguel Sánchez Margallo (Deputy Scientific Director of NANBIOSIS)

Two of the main lines in the activity of the Minimally Invasive Surgery Centre (CCMIJU) are the Innovation and medical training in collaboration with hospitals and companies of the medical sector, with the aim to improve the quality of healthcare delivered to patients, by providing
surgeons and other health professionals with innovative solutions and
training. The CCMIJU is part of the Singular Scientific-Technical Facility
(ICTS) NANBIOSIS, featuring state-of-the-art technology to be
used during the training courses.

Frurther information: Programm and inscriptions

Read More

Combination of stem cell therapy and laparoscopy for the treatment of congenital hernia

Researchers of CCMIJU and NANBIOSIS Unit 14 Cell Therapy, led by Javier García Casado, have recently published a study with the purpose to combine stem cell therapy and laparoscopy for the treatment of congenital hernia in a swine animal model proposing an easy and feasible method to combine stem cell therapy and minimally invasive surgical techniques for hernia repair, the first preclinical study evaluating the use of stem cell therapy in the field of abdominal hernias in a clinically relevant swine model with congenital hernia

Surgical procedures and imaging diagnoses were performed at the ICTS NANBIOSIS Unit 21 Experimental operating rooms, led by Francisco M. Sánchez Margallo

We developed an experimental approach to test whether the use of stem cells for abdominal hernia treatment is viable in a clinically relevant animal model. To the best of our knowledge, this is the first preclinical study where pigs with congenital abdominal hernias were treated with surgical meshes seeded with adult stem cells. Additionally, the surgical approach was performed with minimally invasive procedures to avoid complications related to open surgery. An exhaustive follow-up was performed at different time points using different evaluation methods: ultrasonography, gene expression analysis, complete histological evaluation, and cellular characterization by flow cytometry of infiltrated leukocytes.”

Article of reference:

Laparoscopy for the Treatment of Congenital Hernia: Use of Surgical Meshes and Mesenchymal Stem Cells in a Clinically Relevant Animal. Federica Marinaro, Javier G. Casado, Rebeca Blázquez, Mauricio Veloso Brun, Ricardo Marcos, Marta Santos, Francisco Javier Duque, Esther López, Verónica Álvarez, Alejandra Usón and Francisco Miguel Sánchez-Margallo. ModelFront. Pharmacol., 25 September 2020 https://doi.org/10.3389/fphar.2020.01332

Read More

New project to alleviate the effects of Covid will be developed by JUMISC, partner of NANBIOSIS

The Jesús Usón Minimally Invasive Surgery Center (JUMISC), partner of NANBIOSIS, will develop an R&D project aimed at alleviating the effects of the health and social crisis of COVID-19, thanks to a collaboration agreement with Banco Santander.

The project “Analysis of ligands for SARS-CoV-2 in lymphocyte subpopulations with application for disease staging and patient stratification“, will be developed for a year with the collaboration of researchers from from the San Pedro de Alcántara Hospital in Cáceres, the University of Extremadura, the Reina Sofía Hospital and Mount Sinai in New York.

This research initiative aims to provide a reliable prediction of the development of the disease through the study of certain molecules related to the mechanisms of entry of the virus and how they are altered depending on the age and immune status of the individual. The result of the characterization of SARS-CoV-2 receptors and their correlation with the degree of differentiation of lymphocytes of patients could allow, by means of cytometric analysis, the stratification of patients.The project includes three phases: the first will define a panel of antibodies to identify, by cytometry, those subcellular populations with high levels of expression of ligands for the virus; in the second, the panel of markers already defined will be analyzed and the third will allow to establish groups of patients according to the stage of the disease and predict the evolution of those diagnosed.

For further information, click here

Read More

The Immunomodulatory Signature of Extracellular Vesicles From Cardiosphere-Derived Cells: A Proteomic and miRNA Profiling

Researcher of CCMIJU published an article in the scientific journal FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY with the participation of NANBIOSIS Unit 14 of Cell Stem Cell
Therapy
where culture and in vitro studies were
performed,

The researchers have shown that the regenerative potential and immunomodulatory capacity of cardiosphere-derived cells (CDCs) is mediated by paracrine mechanisms. In this process, extracellular vesicles derived from CDCs (EV-CDCs) are key mediators of their therapeutic effect. Considering the future applicability of these vesicles in human diseases, an accurate preclinical-to-clinical translation is needed, as well as an exhaustive molecular characterization of animal-derived therapeutic products. Based on that, the main goal of this study was to perform a comprehensive characterization of proteins and miRNAs in extracellular vesicles from porcine CDCs as a clinically relevant animal model.

The analysis was performed by identification and quantification of proteins and miRNA expression profiles. The results revealed the presence of clusters of immune-related and cardiac-related molecular biomarkers in EV-CDCs. Additionally, considering that priming stem cells with inflammatory stimuli may increase the therapeutic potential of released vesicles, here we studied the dynamic changes that occur in the extracellular vesicles from IFN gamma-primed CDCs. These analyses detected statistically significant changes in several miRNAs and proteins. Notably, the increase in interleukin 6 (IL6) protein, as well as the increase in mir-125b (that targets IL6 receptor) was especially relevant. These results suggest a potential involvement of EV-CDCs in the regulation of the IL6/IL6R axis, with implications in inflammatory-mediated diseases.

Article of reference: DOI: 10.3389/fcell.2020.00321

Read More

Workshops on Robotic Surgery with experimental models at CCMIJU

This year, CCMIJU, partner of NANBIOSIS, at Cáceres, has organised some new hands-on and customised workshops with robotic technology, expected for 2020 last term.

Specifically CCMIJU is organising, in collaboration with the Enterprise ABEX-Excelencia Robótica SL, some workshops on Robotic Surgery (da Vinci Xi) using experimental models. They are addressed to health professionals from several specialties (urology, gynaecology, general surgery and thoracic surgery) interested in practising with this technology.

The workshops will count on a clinical specialist from ABEX, who will explain the technical features of the robotic equipment, the associated technologies and the virtual simulator for exercises. Subsequently the health professionals, monitored by a tutor-specialist, will be able to practice a surgical approach on the virtual simulator and in vivo, on experimental models.

The mentioned workshops will be developed in a full day, morning- afternoon, in two sessions: virtual simulation an in vivo model. Both of them will be customised and will count on a tutor for surgical training in experimental models.

The focus is to improve the patients’ health care, training surgeons and health professionals in innovative solutions.

For further info, please e-mail  idoiadiaz@ccmijesususon.com

Read More

II Course on introcuction to research and laboratory techniques in biomedicine

JUMISC has organised the Course on introcuction to research and laboratory techniques in biomedicine which wil take place during the month of July, co-Directed by Francisco M. Sanchez Margallo, Deputy Scientific Director of NANBIOSIS  and Javier García Casado, Scientific Director of NANBIOSIS unit 14 Cell Therapy.

Further information and programe: here

Inscriptions: here

Read More

JUMISC will carry out PCR test for COVID-19 infections

The Institute of Health Carlos III (ISCIII), depending of the the Ministry of Science and Innovation, has validated thirty new centers for carrying out PCR tests for COVID-19 infections throughout Spain. The Minimally Invasive Surgery Center, together with the University of Extremadura (JUMISC), partner of NANBIOSIS, will carry out these PCR tests in the laboratory of the veterinary faculty of Cáceres, as it is a P2 biosafety laboratory that is already approved.

They will have the capacity to perform 200 daily PCRs and will work with the samples that the the Extremadura Health Service will send them.

In total, Spain has 54 laboratories to practice the tests that determine COVID-19 infections.

Laboratories validated to carry out these PCR tests have to meet a series of requirements: have personnel trained in molecular biology techniques; have the capacity to work with level 2 infectious samples, biosafety cabinet and adequate equipment; have the capacity to produce inactivation reagents, and manage extraction techniques by their own means that do not subtract capacities from hospital centers, among others

Read More

Microencapsulated Insulin-Like Growth Factor-1 therapy improves cardiac function and reduces fibrosis in a porcine acute myocardial infarction model

Researchers of NANBIOSIS Units at JUMISC. led by Verónica Crisóstomo, Scientific Director of NANBIOSIS unit 24 of Medical Imaging, have just published an article in the Journal Scientific Report

Cardiovascular diseases, especially ischemic heart disease, are the leading cause of mortality worldwide. Conventional treatments have contributed to reduce early mortality after an acute myocardial infarction, but do not recover the damaged myocardial tissue. In the last two decades stem cell therapy has been studied for that purpose. Nowadays it is known now that stem cells are able to secrete combinations of biomolecules that modulate the composition of the damaged cardiac environment contributing to functional tissue repair by stimulating the migration, proliferation and survival of endogenous cardiac progenitor cells as well as attenuating fibrosis and modulating inflammation. Among the secreted substances, there are different cytokines, extracellular vesicles and growth factors including insulin-like growth factor-1 (IGF-1). Our researchers’ goal in this work has been to assess the safety and effectiveness of an intracoronary infusion of microencapsulated IGF-1 after acute myocardial infarction in a clinically relevant swine model of reperfused myocardial infarction.

Large animal studies have been conducted by the ICTS “NANBIOSIS”, more specifically by Units 14, 21, 22 and 24 of the Jesús Usón Minimally Invasive Surgery Centre.

Article:

Báez-Díaz, C., Blanco-Blázquez, V., Sánchez-Margallo, F. et al. Microencapsulated Insulin-Like Growth Factor-1 therapy improves cardiac function and reduces fibrosis in a porcine acute myocardial infarction model. Sci Rep 10, 7166 (2020).

https://doi.org/10.1038/s41598-020-64097-y

Read More

JUMISC will invest 7.3 million in the development of new surgical robots

The Jesús Usón Minimally Invasive Surgery Center (CCMIJU), partner of NANBIOSIS, has been granted the with the FID-CPI Innovative Public Procurement Program of the Ministry of Science and Innovation, as well as with the support of the Ministry of Economy, Science and Digital Agenda of the Board, for the development of the TREMIRS project “Minimally invasive robotic surgery systems” aimed at improve current techniques in laparoscopy and microsurgery

TREMIRS will improve current robotic surgical systems, providing better service to the patient, better ergonomics to the surgeon and greater benefits to the surgical team, achieving an increase in the quality of care. The project is endowed with 7,345,300 euros, and is co-financed 80 percent by the European Regional Development Fund-FEDER.

During the three-year duration of the project, a robotic platform for laparoscopic surgery will be developed that will facilitate new surgical approaches, improvements in the ergonomics of surgeons, advances in vision systems for the entire surgical team and the availability of new portable training tools. .

In the field of microsurgery, TREMIRS will develop a teleoperated robotic platform for reconstructive microsurgery, consisting of robotic microinstruments with high maneuverability and precision, the Board reports in a press release.

It will be used for soft tissue manipulation to perform microsurgical techniques such as anastomosis, suturing, and ligation of small anatomical structures such as blood vessels, nerves, and lymphatic ducts.

The development of both platforms will mean making new equipment available to the National Health System and the Extremadura Health System that is currently not available in the market and that will allow for the improvement of the quality of the services provided to the patient and improvements in surgical results.

Source: https://www.hoy.es/caceres/centro-cirugia-minima-20200419121007-nt.html#vca=fixed-btn&vso=rrss&vmc=tw&vli=C%C3%A1ceres

Read More